UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

Leukemia, 2021-07, Vol.35 (7), p.2119-2124

2021

Volltextzugriff (PDF)

Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes

Haematologica (Roma), 2023-04, Vol.108 (4), p.1196-1199

2023

Volltextzugriff (PDF)

Mobocertinib: Mechanism of action, clinical, and translational science

Clinical and translational science, 2024-03, Vol.17 (3), p.e13766-n/a

2024

Volltextzugriff (PDF)

Measuring patient-reported physical functioning and fatigue in myelodysplastic syndromes using a modular approach based on EORTC QLQ-C30

Journal of patient-reported outcomes, 2021-07, Vol.5 (1), p.60-60, Article 60

2021

Volltextzugriff (PDF)

A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

Journal of patient-reported outcomes, 2019-06, Vol.3 (1), p.35-35, Article 35

2019

Volltextzugriff (PDF)

Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States

PharmacoEconomics - open, 2019-06, Vol.3 (2), p.237-245

2019

Volltextzugriff (PDF)

A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants

Investigational new drugs, 2024-08, Vol.42 (4), p.343-352

2024

Volltextzugriff (PDF)

A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations

International journal of clinical oncology, 2024-10, Vol.29 (10), p.1461-1474

2024

Volltextzugriff (PDF)

XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer

Advanced drug delivery reviews, 2009-11, Vol.61 (13), p.1193-1202

2009

Volltextzugriff (PDF)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

Blood advances, 2022-09, Vol.6 (17), p.5132-5145

2022

Volltextzugriff (PDF)

Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States

Leukemia research, 2018-08, Vol.71, p.27-33

2018

Volltextzugriff (PDF)

A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid Tumors

Clinical cancer research, 2005-11, Vol.11 (21), p.7807-7816

2005

Volltextzugriff (PDF)

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

Leukemia, 2021-12, Vol.35 (12), p.3637-3637

2021

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

Clinical cancer research, 2005-11, Vol.11 (21), p.7825-7833

2005

Volltextzugriff (PDF)

A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent

Leukemia research, 2019-03, Vol.78, p.45-51

2019

Volltextzugriff (PDF)

Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Clinical lymphoma, myeloma and leukemia, 2018-04, Vol.18 (4), p.e157-e166

2018

Volltextzugriff (PDF)

Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care

Leukemia & lymphoma, 2019-01, Vol.60 (1), p.49-59

2019

Volltextzugriff (PDF)

Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review

Clinical lymphoma, myeloma and leukemia, 2018-07, Vol.18 (7), p.e303-e314

2018

Volltextzugriff (PDF)

Pharmacokinetics and Antitumor Efficacy of XMT-1001, a Novel, Polymeric Topoisomerase I Inhibitor, in Mice Bearing HT-29 Human Colon Carcinoma Xenografts

Clinical cancer research, 2012-05, Vol.18 (9), p.2591-2602

2012

Volltextzugriff (PDF)

Mobocertinib efficacy in patients with NSCLC and EGFR exon 20 insertion mutations (ex20ins) identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9082-9082

2023

Volltextzugriff (PDF)

A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of 14C-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants

Investigational new drugs, 2024-08, Vol.42 (4), p.343

2024

Volltextzugriff (PDF)

Phase 3 study of first line pevonedistat (PEV) + azacitidine (AZA) versus single-agent AZA in patients with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (AML)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS7077-TPS7077

2018

Volltextzugriff (PDF)

DNA Methylation Analysis before and during Treatment with Azacitidine Plus Pevonedistat or Azacitidine Alone in Patients with MDS, CMML, and AML Previously Untreated with Hypomethylating Agents

Blood, 2020-11, Vol.136 (Supplement 1), p.29-30

2020

Volltextzugriff (PDF)

Model-based analysis to support dose selection of pevonedistat (PEV) combined with azacitidine (AZA) in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.7042-7042

2021

Volltextzugriff (PDF)

Randomized Phase 2 Trial of Pevonedistat Plus Azacitidine Versus Azacitidine in Higher-Risk Myelodysplastic Syndromes/Chronic Myelomonocytic Leukemia or Low-Blast Acute Myeloid Leukemia: Exploratory Analysis of Patient-Reported Outcomes

Blood, 2020-11, Vol.136 (Supplement 1), p.39-40

2020

Volltextzugriff (PDF)

1 – 25 von 85

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(78)

Publikationsform

Artikel
(84)
Bücher
(1)

Sprache

Englisch
(85)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes

Mobocertinib: Mechanism of action, clinical, and translational science

Measuring patient-reported physical functioning and fatigue in myelodysplastic syndromes using a modular approach based on EORTC QLQ-C30

A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States

A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants

A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations

XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States

A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid Tumors

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent

Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care

Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review

Pharmacokinetics and Antitumor Efficacy of XMT-1001, a Novel, Polymeric Topoisomerase I Inhibitor, in Mice Bearing HT-29 Human Colon Carcinoma Xenografts

Mobocertinib efficacy in patients with NSCLC and EGFR exon 20 insertion mutations (ex20ins) identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA)

A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of 14C-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants

Phase 3 study of first line pevonedistat (PEV) + azacitidine (AZA) versus single-agent AZA in patients with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (AML)

DNA Methylation Analysis before and during Treatment with Azacitidine Plus Pevonedistat or Azacitidine Alone in Patients with MDS, CMML, and AML Previously Untreated with Hypomethylating Agents

Model-based analysis to support dose selection of pevonedistat (PEV) combined with azacitidine (AZA) in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)

Randomized Phase 2 Trial of Pevonedistat Plus Azacitidine Versus Azacitidine in Higher-Risk Myelodysplastic Syndromes/Chronic Myelomonocytic Leukemia or Low-Blast Acute Myeloid Leukemia: Exploratory Analysis of Patient-Reported Outcomes

Suchergebnisse filtern